基于纳夫他林-2-胺基架的Keap1-Nrf2蛋白-蛋白相互作用抑制剂的开发及其抗炎作用
Daisuke Yasuda1, Kai Toyoshima2, Koujin Kojima3
1Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.
ChemMedChem
|September 3, 2025
概括
一种新的pyrrolidine类型的乙化合物强烈激活Nrf2通路,通过准Keap1-Nrf2轴,显示治疗炎症疾病的潜力.
科学领域:
- 医学化学
- 分子生物学
- 药理学
背景情况:
- 核红素因子2相关因子2 (Nrf2) 和凯尔赫类ECH相关蛋白1 (Keap1) 途径是难治疾病的关键治疗点.
- 现有的Keap1- Nrf2蛋白相互作用抑制剂需要进一步的结构开发以提高疗效.
研究的目的:
- 设计和合成新的Nrf2激活剂.
- 评估合成化合物的细胞内Nrf2激活作用.
- 探索已识别的Nrf2激活剂在炎症状况中的治疗潜力.
主要方法:
- 新型基化合物的化学合成.
- 细胞内Nrf2激活的评估.
- 进行X射线共晶学以确定与Keap1的结合相互作用.
- 对Nrf2目标基因mRNA表达的分析 (HO-1,NQO1).
- 对LPS刺激的巨细胞的抗炎作用的评估.
主要成果:
- 一种新型的甲-1,4- ((4- 乙氧硫胺) 衍生物,在2位处具有三级乙胺侧链,显示出强烈的细胞内 Nrf2 激活.
- 皮罗利丁类型的乙胺化合物表现出最强的Nrf2激活,并与Keap1的DC域结合.
- 这种化合物诱导了Nrf2氧酶-1和NAD(P) H:氧降解酶-1的mRNA表达.
- 该化合物在巨细胞系中表现出显著的抗炎作用.
结论:
- 甲-2-乙胺是一种有前途的新型Nrf2激活剂.
- 这种化合物有效地向Keap1-Nrf2通路.
- 它有潜力开发新的炎症疾病治疗方法.
相关概念视频
NF-κB-dependent Signaling Pathway
7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.8K
Regulation of the Unfolded Protein Response
2.6K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.6K


